Optimal therapy of hepatitis C
Open Access
- 1 November 2002
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 36 (S1), S121-S127
- https://doi.org/10.1002/hep.1840360716
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV doseJournal of Hepatology, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis CHepatology, 2001
- Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis CHepatology, 2001
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and CirrhosisNew England Journal of Medicine, 2000
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy dataClinical Pharmacology & Therapeutics, 2000
- National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis CHepatology, 1997